Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
2.540
-0.030 (-1.17%)
Apr 16, 2025, 10:19 AM EDT - Market open
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Aquestive Therapeutics stock have an average target of 11.17, with a low estimate of 8.00 and a high estimate of 17. The average target predicts an increase of 339.76% from the current stock price of 2.54.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aquestive Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 5 | 6 | 6 | 6 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +293.70% | Apr 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +293.70% | Mar 10, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $10 → $8 | Strong Buy | Maintains | $10 → $8 | +214.96% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +293.70% | Dec 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $17 | Buy | Initiates | $17 | +569.29% | Dec 17, 2024 |
Financial Forecast
Revenue This Year
50.59M
from 57.56M
Decreased by -12.11%
Revenue Next Year
70.58M
from 50.59M
Increased by 39.51%
EPS This Year
-0.68
from -0.51
EPS Next Year
-0.58
from -0.68
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 54.6M | 101.9M | 157.5M | ||
| Avg | 50.6M | 70.6M | 104.5M | ||
| Low | 46.0M | 46.1M | 61.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -5.1% | 101.3% | 123.2% | ||
| Avg | -12.1% | 39.5% | 48.0% | ||
| Low | -20.2% | -9.0% | -12.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.64 | -0.55 | 0.06 | ||
| Avg | -0.68 | -0.58 | -0.32 | ||
| Low | -0.77 | -0.63 | -0.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.